

DOREMI - Factors influencing the motivation of the unbalanced type-2 diabetic obese patient in monotherapy by oral diabetes medication

Head :VIGNAL Franck, Sanofi Aventis

Last update : 01/01/2018 | Version : 1 | ID : 83

General

Identification

Detailed name Factors influencing the motivation of the unbalanced type-2 diabetic obese patient in monotherapy by oral diabetes medication

Sign or acronym DOREMI

CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation

CNIL

General Aspects

Medical area Endocrinology and metabolism

Others (details) type-2 diabetes, obesity

Keywords metabolic and cardiological risk factors

Scientific investigator(s) (Contact)

Name of the director VIGNAL

Surname Franck

Phone +33 (0)1 57 63 26 47

Email franck.vignal@sanofi-aventis.com

Unit Sanofi Aventis

Collaborations

Funding

Funding status Private

Details sanofi-aventis france

Governance of the database

Sponsor(s) or organisation(s) responsible Sanofi-aventis France

Organisation status Private

Additional contact

Main features

Type of database

Type of database Study databases

Study databases (details) Not-repeated cross-sectional studies (except case control studies)

Database recruitment is carried out as part of an interventional study Yes

Details Performed at individual level

Database objective

Main objective Describe the factors influencing the motivation of the unbalanced type-2 diabetic obese patient in monotherapy by oral diabetes medication in adhering to the drug and hygiene and dietary care of its cardiometabolic risk factors.

Inclusion criteria Man or woman over the age of 18 years, Type-2 diabetes treated via oral diabetes medication monotherapy, Having a HbA1c rate \leq 6.5%, A BMI \leq 30 kg/m², An abdominal obesity defined according to the NCEP/ATPIII criteria: Waist $>$ 88 cm for women and $>$ 102 cm for men, Able to understand simple recommendations in terms of physical activity and complete a self-evaluation questionnaire

Population type

Age Adulthood (19 to 24 years)
Adulthood (25 to 44 years)
Adulthood (45 to 64 years)
Elderly (65 to 79 years)
Great age (80 years and more)

Population covered Sick population

Gender	Male Woman
--------	---------------

Geography area	National
----------------	----------

Detail of the geography area	France
------------------------------	--------

Data collection

Dates

Date of first collection (YYYY or MM/YYYY)	2008
--	------

Date of last collection (YYYY or MM/YYYY)	2008
---	------

Size of the database

Size of the database (number of individuals)	[500-1000[individuals
--	------------------------

Details of the number of individuals	782
--------------------------------------	-----

Data

Database activity	Data collection completed
-------------------	---------------------------

Type of data collected	Clinical data Declarative data
------------------------	-----------------------------------

Clinical data (detail)	Direct physical measures
------------------------	--------------------------

Declarative data (detail)	Paper self-questionnaire
---------------------------	--------------------------

Presence of a biobank	No
-----------------------	----

Health parameters studied	Health event/morbidity
---------------------------	------------------------

Procedures

Data collection method	type-2 diabetes, metabolic and cardiological risk factors
------------------------	---

Participant monitoring	No
------------------------	----

Links to administrative sources	No
---------------------------------	----

Promotion and access

Promotion

Access

Terms of data access (charter for data provision, format of data, availability delay)

methods for accessing the database are currently being defined

Access to aggregated data

Access on specific project only

Access to individual data

Access on specific project only